Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

22 August 2026 · By · Wire by Fusion42

Published

22 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at lifesciencesipreview.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Teva and Aurinia have settled their patent dispute over the lupus drug voclosporin, allowing Teva to set a launch date for its generic version of Aurinia's Lupkynis.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 21 Aug 2026 and 22 Aug 2026.

◆ ◆ The Wire takeaway

Your generic drug launch timeline just cleared a major legal hurdle. If you build or sell generics, expect accelerated market entry and heightened competition in lupus treatments.

◆ Coverage

2 sources · first reported 21 Aug 2026 · latest 22 Aug 2026

◆ Related on Wire

◆ Topics

Biotechpatent-litigationgenericslupus-drugauriniateva